Journal
SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-05471-w
Keywords
-
Categories
Funding
- LEO Pharma A/S
Ask authors/readers for more resources
This study describes a selective non-steroidal glucocorticoid receptor (GR) agonist, LEO 134310, for topical use, which is rapidly deactivated in the blood resulting in low systemic exposure and a higher therapeutic index compared with currently used glucocorticoids. The selectivity of LEO 134310 for GR was confirmed within a panel of nuclear receptors, and topical treatment with LEO 134310 in minipigs did not result in significant epidermal thinning.
Glucocorticoids (GCs) are commonly used topical treatments for skin diseases but are associated with both local and systemic side effects. In this study, we describe a selective non-steroidal glucocorticoid receptor (GR) agonist for topical use, LEO 134310, which is rapidly deactivated in the blood resulting in low systemic exposure and a higher therapeutic index in the TPA-induced skin inflammation mouse model compared with betamethasone valerate (BMV) and clobetasol propionate (CP). Selectivity of LEO 134310 for GR was confirmed within a panel of nuclear receptors, including the mineralocorticoid receptor (MR), which has been associated with induction of skin atrophy. Topical treatment with LEO 134310 in minipigs did not result in any significant reduction in epidermal thickness in contrast to significant epidermal thinning induced by treatment with BMV and CP. Thus, the profile of LEO 134310 may potentially provide an effective and safer treatment option for skin diseases compared with currently used glucocorticoids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available